Ignite Creation Date:
2025-12-24 @ 5:13 PM
Ignite Modification Date:
2025-12-24 @ 5:13 PM
Study NCT ID:
NCT06654050
Status:
NOT_YET_RECRUITING
Last Update Posted:
2025-12-24
First Post:
2024-10-22
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma
Sponsor:
National Cancer Institute (NCI)
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2025-12-29
Start Date Type:
ESTIMATED
Primary Completion Date:
2027-12-01
Primary Completion Date Type:
ESTIMATED
Completion Date:
2027-12-31
Completion Date Type:
ESTIMATED
First Submit Date:
2024-10-22
First Submit QC Date:
None
Study First Post Date:
2024-10-23
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-12-23
Last Update Post Date:
2025-12-24
Last Update Post Date Type:
ACTUAL